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Abstract 
Ethnopharmacological relevance: Artemisia afra (Asteraceae) is a traditional 
medicinal plant frequently used in steam inhalation form to treat respiratory 
conditions. 
Aim of the study: Quantify luteolin content in Artemisia afra dried crude and 
aqueous extract. Evaluate the pulmonary effects of Artemisia afra steam 
inhalation, nebulized Artemisia afra extract and luteolin in isolated perfused lungs 
(IPL). Evaluate the pulmonary disposition of intravenously administered luteolin. 
Materials and methods: HPLC was used to quantify luteolin in Artemisia afra 
extracts. A modiﬁed version of the IPL was used to determine the effects of 
Artemisia afra steam inhalation, nebulized luteolin, and nebulized aqueous leaf 
extract on lung function, as well as the pulmonary disposition of IV luteolin. 
Results: Artemisia afra extract contained signiﬁcantly higher luteolin levels 
than the crude dried leaves. Inhaled Artemisia afra steam, and nebulized 
luteolin, and Artemisia afra extract and IV luteolin produced signiﬁcant dose-
dependent improvements in lung function, with nebulized Artemisia afra 
producing the greatest improvements. Nebulisation with Artemisia afra extract 
yielded higher quantities of luteolin than luteolin nebulisation. 
Conclusion: Results verify the traditional use of inhalation of Artemisia afra 
steam, although nebulized luteolin  and  aqueous  extract  are  better  alternatives.  
Luteolin  signiﬁcantly contributes  to  the  broncho-dilatory effects of Artemisia 
afra. 
 
1.  Introduction 
Traditional medicines remain a source of viable alternatives for affordable healthcare 
especially in developing countries (Mayosi et al., 2009). In South Africa an estimated 70% 
of the population depend on traditional medicines largely comprising of plants such as 
Artemisia afra Jacq. ex Willd (Asteraceae) for treatment of a wide variety of diseases 
(Mander et al., 1997). 
 
Artemisia afra, a multi-stemmed perennial shrub with greyish- green feathery leaves, 
enjoys widespread use in traditional med- icines in South Africa for the treatment of a 
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wide variety of illnesses. The most prevalent use is for the treatment of respiratory 
disorders such as coughs, colds, bronchitis, blocked sinuses and tight-chest or asthma 
in the form of a steam inhalation of the leaves (Roberts, 1990; Iwu, 1993; Van Wyk and 
Gerike, 2000a). Extracts of the plant leaves have been shown to exhibit various 
pharmacological effects including relaxation of respiratory smooth muscles contracted by 
various known bronco-constrictors, but the bronchodilatory effect of the plant in the 
form that it is used in traditional medicine (steam inhalation) is yet to be assessed in 
intact lungs and the exact plant chemical constituents responsible for  this  activity  is  still  
unknown (Roberts, 1990;  Van  Wyk  and Gerike, 2000b; Waithaka, 2004). 
 
Flavonoids, found in appreciable quantities in Artemisia  afra, have been suggested to be 
responsible for the  bronchodilatory effect of the extracts (Harris, 2002). Artemisia afra 
contains several ﬂavonoids, including apigenin, chrysoeriol, tamarixetin, acacetin, 
genkwanin and kaempferol (Kraft et al., 2003; Waithaka, 2004; Avula et al., 2009) with 
the aqueous extract containing greater quantities of luteolin and quercetin than the other 
ﬂavonoids (Muganga, 2004; Waithaka, 2004;  Mukinda et  al., 2010). These 2 ﬂavonoids 
are also easily extractable from the plant, stable under various processing conditions, and 
selectively quantiﬁable using HPLC, thus making them ideal markers when evaluating 
Artemisia afra extracts, (Markam, 1982; Harborne and Williams, 2000; Waithaka, 2004; 
Springﬁeld et al., 2005, Mukinda et al., 2010). Luteolin however with its greater 
quantities (Muganga, 2004; Waithaka,  2004),  anti-inﬂammatory,  antispasmodic   
(Yamazaki et al., 2002),  and  muscle  relaxant  activity  (Sanchez  de  Rojas et al., 1995; 
Harris, 2002; Das et al., 2003) is the ideal candidate for a marker compound. 
 
Although the pharmacokinetics and bioavailability of luteolin has been studied using 
various models, the pharmacokinetics following  pulmonary  administration  is  yet  to  be  
carried  out (Shimoi et al., 1998; Spencer et al., 1999; Scalbert and Williamson, 2000; Wang 
et al., 2003; Muganga, 2004; Lui et al., 2005, Mukinda et al., 2010). To study the 
pharmacokinetics of luteolin in the lungs as well as the effects of Artemisia afra on lung 
parameters, the isolated perfused lung (IPL) model was chosen. It provides a suitable 
model for measuring the delivery and pharmacokinetics of Artemisia afra in the lungs as 
well as the effect on pulmonary parameters such as lung resistance and compliance whilst 
mini- mizing the inﬂuence of the nervous system, hormones, and chemical mediators 
circulating in plasma. It also allows for the simultaneous measurement of respiratory 
mechanics such as tidal volume, lung compliance, and resistance and can easily be adapted 
for administration via inhalation, instillation, bolus injection or continuous perfusion 
(Uhlig and Wollin, 1994; Uhlig and Taylor, 1998; Mjiqiza, 2006). 
 
In this study, the isolated perfused lung (IPL) model was used to evaluate the pulmonary 
effects of the traditionally-prepared Artemisia afra steam inhalation, nebulized Artemisia 
afra aqueous extract and luteolin solutions.  Luteolin content  in dried  crude Artemisia  
afra  leaves  and   an   aqueous   extract   of   Artemisia afra leaves were quantiﬁed using 
HPLC and the pulmonary disposition and effect of intravenously administered luteolin in 
IPL determined. 
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2. Materials and methods 
2.1 Chemicals and reagents 
Sodium chloride, potassium chloride, calcium chloride 2-hydrate, potassium dihydrogen 
phosphate, magnesium chloride 6-hydrate, sodium hydrogen carbonate and glucose (all of 
analytical grade; Holpro Analytics Pty Ltd., Johannesburg, South Africa); bovine serum 
albumin (Fraction  V), luteolin (97%) and dimethyl sulfoxide  ( all Sigma-Aldrich, South 
Africa, Vorna Valley, South Africa); heparin sodium (Fresenius Kabi (Pty) Ltd., Cape Town, 
South Africa); sodium pentobarbitone (Kyron Laboratories (Pty) Ltd., Johannesburg, South 
Africa); carbon dioxide, helium and  nitrogen (all from Afrox Ltd, Epping, South Africa); 
concentrated hydrochloric  acid,  methanol, and acetone (all analar grade; KIMIX Chemicals 
& laboratory suppliers, USA); acetonitrile (HPLC grade, ACS speciﬁcations, Allied Signal 
Inc.); and formaldehyde and ethyl acetate (AR Saarchem Merck Chemicals (PTY) LTD), were 
used in the preparation of the plant materials, the assay of the plant materials, lung and 
perfusate samples and the isolated perfused lung experiments. 
 
2.2 Preparation of Artemisia afra extracts 
Artemisia afra was obtained from Montague museum (Montague, South Africa) and 
identiﬁed by Riaan Cedras at the herbarium at UWC (voucher specimen 6735). Fresh 
leaves were dried at 30 1C for 72 h in a well-ventilated oven until a constant weight, and 
ground to a ﬁne powder. Aqueous extraction of 100 g of dried ground plant leaves with 1 
L of boiling distilled water for 30 min was carried out, and the resultant infusion ﬁltered, 
and freeze-dried to produce a dry ﬂaky brownish extract. The resultant aqueous extract was 
stored in a desiccator in sealed amber bottles until further use. 
 
2.3 HPLC assay for the determination of luteolin levels 
The HPLC assays used in the study were all validated for separation and speciﬁcity, 
inter- and intra-day variability, recov- ery, linearity and lowest limit of detection. HPLC 
assays of un- hydrolyzed and hydrolyzed dried leaves and aqueous extract were carried 
out to quantify luteolin (aglycone and glycoside) levels in Artemisia afra. To prepare un-
hydrolyzed Artemisia afra for HPLC assay, 25 mg of the aqueous extract and 100 mg of 
the dried leaves were dissolved in 300 ml and 1 ml of distilled water respectively. The 
internal standard, Morin (100 ml) was added to each sample, the contents thoroughly 
vortex-mixed for 1 min, and thereafter extracted with 5 ml ethyl-acetate. To produce 
hydrolyzed samples 4 ml of 2N HCl was added to the vortexed mixture and heated in a 
water-bath at 80 1C for 40 min, cooled to room temperature, and extracted with 5 ml of 
ethyl-acetate. The ethyl-acetate  extracts were evaporated to dryness under a gentle stream 
of nitrogen gas, the residue re-dissolved into 500 ml of the mobile phase and 100 ml of the 
solution run on a Beckman System Gold HPLC system (32-Karat™ software package) 
consisting  of  a  programmable binary gradient pump (Beckman Gold Module 126 series), 
an auto sampler (Beckman Gold Module 507 series) with a diode array detector 
(Beckman Gold Module 168 series) (all Beckman, USA) and a Lunas C-18 reverse phase 
column (Phenomenex, USA). Eluting solvent was a mixture of acetonitrile and phosphate 
buffer (100 mM, pH 2) (3:7) pumped isocratically at a ﬂow rate of 1 ml/min. The luteolin 
peaks were detected at the wavelength of 349 nm. 
http://repository.uwc.ac.za
4 
 
 
2.4.   The isolated perfused lung system 
Male Wistar rats (300–400 g) obtained from the University of Cape Town (UCT) and the 
Medical Research Council (MRC), South Africa were used in this study. The animals were 
kept on a 12-h light/12-h darkness cycle in a well-ventilated animal room and allowed free 
access to food and water.  All  animal  experiments were conducted in accordance with the 
internationally accepted principles for laboratory animal use and care, and the protocol as 
approved by the ethics committees of the MRC and University of the Western Cape 
(UWC). 
 
A modiﬁed version of the isolated perfused lung (IPL) system as described by Uhlig and 
Taylor (1998) was used to determine the effects of Artemisia afra steam inhalation, 
nebulized luteolin, and nebulized aqueous leaf extract on lung function, as well as the 
pulmonary disposition of intravenous administered luteolin. In this system, the 
jacketed organ chamber was ﬁtted with a pneumotachometer to measure air ﬂow rate, 
while the lungs were perfused via a pulmonary arterial cannula connected to a peristal- tic 
pump, and discharged via a pulmonary venous cannula. A bubble trap in the 
pulmonary arterial cannula allowed for the bolus administration of drugs and also 
contained a pressure transducer used for the continuous measurement of pulmonary 
arterial pressure (PAP). The lung chamber was also linked to a chamber pressure  
transducer for measuring  trans-pulmonary pressure (chamber pressure). Ventilation of 
the lung was achieved by a ventilation control module (VCM) connected to the trachea 
via a tube containing a change-over valve that allowed for the switch of ventilation 
between negative and positive pressure ventilation. The respiratory rate and the level of 
the end- expiratory and end-aspiratory pressures were controlled by the VCM settings 
while the frequency of deep breaths (“sighs”) was adjusted through the timer counter 
module (TCM). 
 
Male Wistar rats (300–400 g) were anaesthetized with sodium pentobarbitone (100 
mg/kg; IP), tracheotomised with a cannula and ventilation at positive pressures of 
about 10 cm H2O and 80 breaths/min started. The animal was then exsanguinated, and 
the upper abdomen and thorax dissected to expose the lungs. The right ventricle was 
cannulated with an arterial cannula, while the left atrium was cannulated with a venous 
cannula. Perfusion with the perfusion ﬂuid was then initiated at 5 ml/min while the lungs 
were dissected free of the animal and placed in the artiﬁcial thorax chamber (Uhlig and 
Wollin, 1994). Positive pressure  ventilation was then stopped and lungs switched to 
negative pressure ventilation with the pressure in the chamber ﬂuctuating between an 
end-inspiratory pressure of - 10 to - 16 cm H2O and end- expiratory pressure of - 2 
cm H2O. Perfusion ﬂow rate was also increased to 25 ml/min and a pneumotachometer 
connected to the external input module (EIM) via a differential pressure transducer 
(Validynes, model DP45-24) and an ampliﬁer (model SP 2040D) inserted into the 
organ chamber to measure the airﬂow rate. Perfusion ﬂuid (Krebs-Henseleit buffer 
containing calcium chloride 2.5 mM, Magnesium sulfate 1.2 mM, sodium chloride 118 
http://repository.uwc.ac.za
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mM, potassium  chloride  4.7 mM,  potassium  dihydrogen  phosphate 1.2 mM, 2% 
bovine serum albumin (BSA), and 0.1% glucose; pH 7.3–7.4) was pumped through the 
lung vasculature using single pass perfusion for 5 min to clear the organ debris before 
changing to recirculation mode for the rest of the experiment to mimic the normal  body  
circulation.  Lungs  were  allowed   to   equilibrate and stabilize for 20 min before 
treatment with test compounds. At the end of each experiment, the lungs were assessed  
for edema formation, and separated from the trachea and the heart before being weighed 
on an electronic balance. During experi- ments tidal volume, mean pulmonary  pressure,  
airﬂow  rate and trans-pulmonary pressure  were continuously monitored  via the 
PLUGSYS™ system on a computer. Lung resistance (LR) and compliance (LC) values were 
determined automatically from air- ﬂow rates and pulmonary pressure readings by the 
PULMODYN™ computer software. In order to determine the viability of the model, lungs 
were perfused with perfusate for 2 h and were found to be stable with the following values 
for pulmonary parameters at the start and end of perfusion: tidal volume (4.3670.16– 
3.4870.91); lung resistance (0.5270.07–0.6170.05) and lung compliance (0.6470.57–
0.5870.17). 
 
2.5 Effects of traditionally prepared Artemisia afra steam inhalation on 
lung function 
To determine the effects of traditionally prepared Artemisia afra steam inhalation on 
lung function, dried leaves of Artemisia afra were boiled for 5 min and the resulting 
steam introduced into the IPL system via 3 cooling and condensation chambers with 
com- pressed air used to drive the stream of the resultant vapor in the direction of the 
organ chamber. The lungs were allowed to inhale the steam for 3 min under negative 
ventilation and thereafter lung function monitored for 30 min. A second outlet of the 
steam- feeder was immersed in 1 ml of distilled water during steam inhalation to trap 
aerosolized compounds and the sample sub- jected to HPLC analysis to identify and 
quantify the amount of luteolin aerosolised during the steam inhalation period. Control 
lungs received 3 min of inhaled steam from 100 ml saline, while test lungs received 
steam from either 10 mg/ml (1 g in 100 ml saline) or 50 mg/ml (5 g in 100 ml saline) 
Artemisia afra. 
 
2.6 Effects of nebulized luteolin and aqueous Artemisia afra extract on 
lung function 
To determine the effects of nebulized luteolin and the aqueous extract of Artemisia afra on 
lung function, a jet nebulizer used to generate the aerosol was linked via a thin silicone 
tube to the thorax chamber. The lungs were nebulized for 3 min under negative 
ventilation either with 4 ml of saline (control), 4 ml saline containing 250 mg luteolin per 
1 ml of saline or 4 ml saline containing 100 mg Artemisia afra aqueous extract per 1 ml  of 
saline (equivalent to 250 mg luteolin per ml of saline). Lung function was monitored  
thereafter for 30 min. During nebulisa- tion, a second outlet of the nebulizer feeder was 
immersed in 1 ml of distilled water to trap aerosolized compounds, and the sample 
analyzed with HPLC to identify and quantify the amount of luteolin trapped during the 
nebulization period. 
http://repository.uwc.ac.za
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2.7 Disposition and effect of IV administered luteolin in IPL 
To determine the effect and disposition of luteolin in the lungs, the following procedure 
was followed. Lungs were perfused with a perfusion solution containing either 2 mg/ml 
or 10 mg/ml of luteo- lin for 90 min. During luteolin perfusion, 1 ml samples of perfusate 
were collected at 3, 5 10, 15, 30, 45, 60, 75 and 90 min and stored at 2 1C for later 
analysis. Perfusate samples were then divided into 2 x 500 ml samples to assay for 
luteolin in hydrolyzed and un- hydrolyzed samples. Each 500 ml perfusate was spiked 
with 10 mg morin (internal standard), vortex-mixed and then 1 ml methanol added to 
precipitate proteins. Un-hydrolyzed samples were then directly extracted with 5 ml of 
ethyl-acetate, while for hydrolyzed samples, 2ml of 2N HCL was added to each sample, 
heated in a water bath at 80 1C for 40 min, cooled to room temperature, and extracted 
with 5 ml of ethyl acetate. Ethyl acetate extracts were evaporated to dryness under a 
stream of nitrogen gas, the residue re-dissolved into 500 ml of HPLC mobile phase, and 
100 ml of the solution injected into HPLC column for analysis. 
 
2.8 Data  analysis 
To determine the changes in lung mechanics after treatment with the different plant 
compounds, the following parameters were observed: tidal volume (TV), lung compliance 
(LC) and resistance (LR) (calculated using the PULMODYN Software). Mean values (n ¼ 5) 
at each speciﬁed time interval was calculated and two-way ANOVA analysis followed by 
the Bonferroni post test or t- test analysis used to determine the statistical signiﬁcance. To 
determine the levels of luteolin in the plant extracts and the efﬂuent perfusate, luteolin and 
morin peak heights were obtained from the HPLC 32-Karat software package generated 
data, and the luteolin to morin peak height ratios calculated using Excel. The 
concentration vs. ratios data were then subjected to linear regres- sion analysis, and used 
for construction of the standard curve and luteolin concentrations determined from the 
same standard curve using Graphpads Prism software. 
 
3.  Results 
3.1 Identiﬁcation and quantiﬁcation of luteolin in the plant material 
The developed HPLC assay was fairly robust, linear over the concentration range of 5–30 
mg of luteolin/ml solution with a correlation coefﬁcient (r2) of 0.9916. The assay had high 
assay reproducibility (i.e. CV below 3%), was quite sensitive with a LLQ of 70 ng  on column, 
and therefore deemed suitable for the study. Hydrolyzed and un-hydrolyzed forms of the 
aqueous extract and dried leaves of Artemisia afra were analyzed by HPLC assay. Each 
extract produced distinct peaks for luteolin with a retention time of 14.4370.298 min, 
which were easily quantiﬁable (Fig. 1 and Table 1). Additional peaks with much shorter 
retention times than luteolin and morin (internal standard) were evident in the 
chromatograms, with the peaks from the solutions of the hydro- lyzed extract being more 
prominent than that of the hydrolyzed leaves (Table 1). 
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3.2 Effect of Artemisia afra steam inhalation, nebulized freeze-dried 
Artemisia afra aqueous extract and nebulized luteolin on lung mechanics 
3.2.1 Effect on tidal volume 
Steam inhalation from 1 g and 5 g quantities (10 mg/ml and 50 mg/ml) of the dry leaves 
of Artemisia afra boiled in 100ml of normal saline led to no statistically signiﬁcant initial 
changes in tidal  volume  (TV)  post  exposure—3.6%  (from  4.1970.129 ml  to 4.3470.140 
ml) and 7.6% (from 4.2270.120 ml to 4.5470.088ml) respectively (Fig. 2). 
 
 
 
 
 
This was however followed by a decrease at a steady rate of 0.014470.0042 ml/min for 10 
mg/ml, while the increase in TV from the 50 mg/ml dose was sustained for 16 min 
before decreasing at a steady rate similar to that of the 10 mg/ml and saline group of lungs. 
Nebulizing the lungs with luteolin (250 ug/ml) led to a statistically signiﬁcant (11%)  
increase  in  TV  (from 3.8670.078 ml  to  4.2570.189 ml)  which  was  sustained  for  the 
duration of the post-nebulization period (Fig. 2). Nebulizing with Artemisia afra aqueous 
extract also led to a statistically signiﬁcant (18%) increase in TV, which was greater than 
that produced by all other drugs, and sustained throughout the monitoring period (Fig. 2). 
http://repository.uwc.ac.za
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Perfusion with luteolin (2 mg/ml and 10 mg/ml) led to no statistically signiﬁcant initial 
changes in TV ( 5.6% and 13.7% decreases respectively). However, post-perfusion rate 
of decrease was statistically signiﬁcantly less than the pre-treatment rate for both doses 
indicating that luteolin administered into the perfusion media stabilized the tidal volume 
(Fig. 2). 
 
3.2.2.   Effect on lung compliance 
Steam inhalation of Artemisia afra leaves led to statistically signiﬁcant dose-
dependent increases in lung compliance (LC), with  the  10 mg/ml  and  50 mg/ml  doses  
increasing  LC  by  3.4% (from 0.6270.022 ml/cm H2O to 0.6470.019 ml/cm H2O) 
and 11.8% (from 0.5970.026 ml/cm H2O to 0.6670.027 ml/cm H2O) respectively (Fig. 3). 
Increase in LC with the lower dose was sustained for only 20 min, while the increase  from  
the  higher dose was sustained throughout the experimental period. 
 
Nebulizing the lungs with luteolin (250 ug/ml) led to a statistically signiﬁcant  36.4%  
increase  in  LC  (from  0.6570.012 ml/cm H2O to 0.8870.019 ml/cm H2O) (Fig. 3). This 
improvement was sustained for the entire post nebulization monitoring period. When the 
lungs were however nebulized with Artemisia afra extract equivalent to 250 ug/ml of 
luteolin, LC improved by 43.4% (from 0.7070.029 ml/cm H2O to  1.0070.043 ml/cm  
H2O), and only exhibited a slight decline during the monitoring period (Fig. 3). 
Intravenous perfusion with luteolin (2 mg/ml) produced an initial non-statistically 
signiﬁcant (1%) change in LC (from 0.5170.039 ml/cm H2O to 0.5170.047 ml/cm H2O) 
(Fig. 3). Lung compliance however increased at a  steady  rate  (0.005587 0.00289 ml/cm 
H2O/min) throughout the posttreatment period leading to a peak value (1.0270.093 
ml/cm H2O) representing a statistically signiﬁcant 98.5% increase. The higher luteolin (10 
mg/ ml) dose also produced an initial non-statistically signiﬁcant (1.9%) change in LC 
(from 0.5470.034 ml/cm H2O to 0.5570.039 ml/cm H2O), also followed by a steady rate 
(0.0072170.00113 ml/cm H2O/min) increase over the post treatment period to a 
statistically signiﬁcant higher ﬁnal value of 1.1770.028 ml/cm H2O (Fig. 3). 
 
3.2.3.   Effect on lung resistance 
Steam inhalation with and 50 mg/ml Artemisia afra leaves extract led to an initial 
statistically signiﬁcant decreases in lung resistance (LR) (9.7% and  11%  respectively).  This  
was  however  followed  by an increases at steady  rates  similar  to  and  slightly  higher  than 
the   pre-inhalation   rate   for   the   10 mg/ml   (0.0031170.00148 cm H2O s/ml/min) and 
50mg/ml (0.0058470.00096 cm H2O s/ml/min) doses respectively (Fig. 4). 
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Nebulizing the lungs with luteolin (250 ug/ml) led to an initial statistically signiﬁcant 
19.7% decrease in LR (from 0.6670.014 cm H2O s/ml to 0.5370.014 cm H2O s/ml), 
followed by an increase at a steady rate (0.0057470.0009 cm H2O.s/ml/min) similar to 
the post-nebulization rate of increase in the saline group. Artemisia afra extract 
nebulisation on the other hand also led to a statistically signiﬁcant though smaller 
decrease in LR (by  8.5%; from   0.6370.013 cm   H2O s/ml   to   0.5770.038 cm   H2O 
s/ml). This  decrease  unlike  that  produced  by  luteolin  was  sustained throughout the 
post-nebulization period (Fig. 4). 
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Intravenous perfusion with luteolin (2 mg/ml) led to an initial non-statistically  signiﬁcant  
change   in  LR  (from  0.5670.065 cm H2O s/ml to 0.5570.065 cm  H2O s/ml),  with  a  
further  decrease (to 0.4170.077 cm H2O s/ml) occurring after 10 min post-perfusion 
followed by an increase (to 0.4970.044 cm H2O s/ml) after 25 min, and then a gradual 
decline followed by a slight increase towards the end of the monitoring period to levels 
which were statistically signiﬁcantly lower than the pre-treatment levels. The higher luteolin 
dose (10 mg/ml) induced an initial statistically signiﬁcant increase in LR (from 0.4170.052 
cm H2O s/ml to 0.5770.063 cm H2O s/ml), followed by a brief, sharp drop  to  
0.406070.07716 cm  H2O s/ml after 10 min, then  a  subsequent  steady  increase  in  levels  
over 35 min, and ﬁnally a gradual decrease to values that remained signiﬁcantly higher than 
the pre-treatment LR levels at the end of the post treatment period (Fig. 4). 
 
3.3.   The disposition proﬁle of intravenously administered luteolin in the 
IPL 
Analysis of luteolin levels in lung perfusion medium indicated that  pre-perfusion  the  2 
mg/ml  luteolin  perfusate  contained 1.9670.0143 mg/ml free (un-hydrolyzed luteolin), 
while a comparable 1.9870.0074 mg/ml was obtained after acid hydrolysis. For the 
higher dose (10 mg/ml), free luteolin was 9.8670.0933 mg/ml and aglycone luteolin 
level was 9.8770.0098 mg/ml, conﬁrming that no alteration in luteolin levels 
occurred in the albumin containing perfusion medium. 
 
Levels of free luteolin in the lung perfusate ﬁrst increased slightly, then decreased at 
a rapid rate (0.1870.002086 mg/ml/ min) for about 30 min, followed by a slower 
rate of decrease (0.4970.003674 mg/ml/min) to the end of the perfusion period. The 
ﬁrst order rate constant and half-life for the terminal phase were 8.73 x 10- 3 min- 1 
and 79.381 min, respectively. For the higher luteolin dose (10 mg/ml), the free luteolin 
perfusate levels ﬁrst increased to 7.4070.1647 mg/ml, decreased at a steady rate 
(0.5970.0019 mg/ml/min) for 5 min before increasing steadily (0.4270.01667 
mg/ml/min) until the end of the perfusion period. The ﬁrst order rate constant and 
half-life for the terminal phase were 2.501 x 10- 4 min- 1 and 2770.89 min, respectively 
(Table 2). 
 
4.  Discussion 
Traditionally prepared Artemisia afra aqueous extract contained higher content of 
luteolin than the freeze-dried extract, with approximately 50% of luteolin in acid-
hydrolyzable, presumably glycoside  form.  Higher concentrations of luteolin have been 
extracted  from  the  plant  and  the  lower  concentrations  isolated here is most likely 
due to the nature of the solvent used in the process (Muganga, 2004). The results 
conﬁrmed the presence of quantiﬁable amounts luteolin in Artemisia afra extracts as 
previously reported by other researchers (Muganga, 2004; Waithaka, 2004), indicating 
the possibility that luteolin may be implicated in any effect the extracts have on the 
lungs. 
http://repository.uwc.ac.za
11 
 
 
 
 
 
For this study the IPL was a particularly useful and novel tool to evaluate both the 
pulmonary effect of, and the pulmonary availability of an active  constituent (luteolin)  
in  Artemisia afra, as it would be administered traditionally, i.e. in steam inhalation 
form. Moreover changes in the pulmonary parameters such as TV, LR and LC are 
particularly appropriate and sensitive indicators of anti-asthmatic activity. Tidal volume 
is the volume of gas inspired or expired during each respiratory cycle. It usually 
decreases during bronchoconstriction and increases during bronchodilation, and is 
often affected during pulmonary disorders such as asthma and COPD (Ruppel, 2004). 
Compliance is the volume change per unit of pressure change for lungs and is measured 
in millimeters per centimeter of water (ml/cm H2O) (Ruppel, 2004). CL is an index of 
functional stiffness of the lung and reﬂects changes to small airways, thus making 
compliance a useful test to indicate changes in periphery of the lung (Drazen, 1984). It 
is normally decreased in pulmonary edema or congestion, atelectasis, pneumonia and 
restrictive diseases such as pulmonary ﬁbrosis and asthma. Known bronchodilators 
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usually increase the lung compliance (Ruppel, 2004). Finally, airway resistance (RL) 
is deﬁned as the pressure difference required for a unit ﬂow change and is usually 
measured in centimeters of water per milliliter per second. It is the measurement of 
clinical and physiological interest, and is useful for evaluating the respiratory effects of 
bronchodilatory or bronchoconstrictive drugs. Increased resistance is usually due to 
narrowing and collapse of airways and clinically related to an assortment of respiratory 
diseases such as asthma and bronchitis (Lausted and Johnson, 1999;  Ruppel,  2004). 
 
Steam inhalation of Artemisia afra induced dose-dependent increases in TV and LC, 
while leading to decreases in LR. These effects were similar to those obtained with 
known bronchodilators suggesting that the plant contained compounds with 
bronchodilatory activity (Svens and Rvrfeldt, 2001). Since luteolin a ﬂavonoid found 
in Artemisia afra and previously associated with bronchodilatory activities (Das et al., 
2003) was found in signiﬁcant quantities in the extract, it probably played a role in the 
observed effects of the steam inhalation. Flavonoids have been reported to trigger the 
release of pulmonary surfactants which in turn reduce the surface tension in the lung 
tissues, thus reducing airway resistance, while also increasing the elasticity of the lung 
and hence LC (Niemeier, 1984). Lung compliance was increased in particular possibly 
via a variety of factors, including increased lung elasticity, smooth muscle relaxation or 
improved activity of the pulmonary surfactant (Niemeier, 1984). Improved activity of 
the pulmonary surfactant due to other constituents of the extract may in particular 
explain the better effect obtained with the  extract than with luteolin. However HPLC 
analysis of the post-lung condensate from the extract did not detect luteolin. This 
suggests that either luteolin levels were below the limit of detection or that the 
bronchodilator effects were due to other compounds such as volatile oils like thujone 
(Roberts, 1990). 
 
Nebulized luteolin also exhibited a bronchodilatory effect, with dose-dependent 
improvements in lung function (increased TV, LC and decreased LR) greater than those 
obtained with the steam inhalation Artemisia afra. This ordinarily would have 
suggested that luteolin was responsible for  the  bronchodilatory  effects  of the plant, 
except that the nebulized Artemisia afra extract produced even greater improvements 
in lung function. Nebulized Artemisia  afra  also  sustained the  improved lung  
function better than Artemisia afra steam inhalation or nebulized luteolin despite 
containing luteolin equivalent in dose to the nebulized luteolin dose. The improvement 
in lung function with nebulized luteolin indicate that luteolin does play a role in 
Artemisia afra effect, but improved effect with the nebulized extract suggests the 
presence of either other active constituents (possibly ﬂavonoids such as quercetin) or 
complimentary compounds in the plant. There is also the possibility of improved 
bioavailability of luteolin from the plant extract possibly due to surfactant effect from 
other contained ﬂavonoids. Higher luteolin yields in post-lung condensate from 
nebulized plant extract than from luteolin correlates with studies showing a better 
release and greater bioavailability of luteolin when contained in plant material than its 
aglycone form suggesting that the improved efﬁcacy was due to the improved 
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bioavailability of the extract (Markam, 1982; Muganga, 2004). Once more despite the 
evidence of the effect of luteolin on lung function, luteolin was not detected in the 
perfusate after the inhalation of the nebulized luteolin or Artemisia afra aqueous 
extract solutions. It may be that luteolin levels in the perfusate were  below  the lower 
limit of detection of the HPLC assay used in this study, or that the compound had a 
poor disposition in the lungs or was rapidly metabolized amongst other reasons 
(Tronde, 2002). 
 
Luteolin was administered IV to study its disposition proﬁle in the lungs at levels that 
produced comparably changes to lung dynamics as inhalation and nebulisation. 
Intravenously administered luteolin improved lung function similar to the effects 
obtained with steam inhalation and nebulisation, further conﬁrming its 
bronchodilatory effect. A direct correlation between an increase in LC and a decrease 
in perfusate luteolin levels (indicative of luteolin uptake and/or metabolism) strongly 
suggests that the improved LC was due to luteolin activity. In fact, luteolin seems to 
particularly increase the lung compliance, an effect that might be caused by a variety 
of factors, including increased lung elasticity, smooth muscle relaxation or improved 
activity of the pulmonary surfactant (Niemeier, 1984). Further studies comparing the 
luteolin perfusate levels and its lung effects  must however, be done before one can 
truly conﬁrm such hypothesis. Nevertheless, this study strongly suggests that luteolin 
could be a worthy marker to monitor, establish and quantitate the pulmonary effects of 
Artemisia afra. 
 
Nebulization produced better and more sustainable pulmonary effects than steam 
inhalation. There may be a variety of reasons for this, including that nebulization 
provided better deposition of plant actives in the lung than the steam inhalation. The 
administration of nebulized Artemisia afra extract could thus be a better alternative 
to the traditionally-used steam inhalation for the treatment of respiratory conditions, 
provided that other factors (such as convenience, availability of nebulizer) are also 
considered and dealt with. 
 
In conclusion, inhalation of Artemisia afra steam and nebulized Artemisia afra extract 
and luteolin and intravenously-administered luteolin produced improvements in lung 
function similar to that obtained with known bronchodilators (Svens and Rvrfeldt, 
2001). Artemisia afra extracts containing appreciable amounts of luteolin produced 
pulmonary effects similar in magnitude to that of luteolin, suggesting that luteolin 
could be an important contributor to the pulmonary effects of Artemisia afra. 
 
Though it was not the objective of this study to determine the mechanism of action of 
luteolin or Artemisia afra effect on the lungs, but it could be speculated that this 
would include smooth muscle relaxation, and improved surfactant activity (Das et al., 
2003). While the above results clearly indicate that Artemisia afra improved lung 
function in a similar way to luteolin, and that luteolin could therefore, be associated 
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with the pulmonary effects produced by Artemisia afra, the mechanism for this effect 
is yet to be established. 
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